Abbott Laboratories

Rank: 20
2016 Rank24
Employeesn/a
Revenue:$5,233,000,000
R&D Spend:n/a
Fiscal year ending:12-31-16
Click here to see all 100

Abbot moved from 24th to 20th in 2016, and there’s every indication that by 2018 it will have risen higher in the ranks, thanks to its $25 billion acquisition of St. Jude Medical in January 2016.

In August, the FDA approved HeartMate 3, a bridge-to-transplant cardiac assist device that pumps blood for heart-failure patients using a fully magnetically levitated impeller that simulates the beating of a heart. The HeartMate 3 device is among key products in the St. Jude Medical portfolio, along with the other major launch this year, Tacticath, a contact force enabled catheter.

And Abbott is also making moves in the diabetes space, inking a deal with Bigfoot Biomedical, integrating its FreeStyle Libre glucose sensing technology with Bigfoot’s insulin delivery solutions.

* Revenues from Abbott’s medical device segment.


Big 100 Mini Logo Key Personnel: Miles White, chairman & CEO; Hubert Allen, EVP, general counsel & secretary; Brian Blaser, EVP, diagnostics; John Capek, EVP, ventures; Robert Ford, EVP, medical devices; Stephen Fussell, EVP, HR; Andrew Lane, EVP, established pharmaceuticals; Heather Mason, EVP, nutritional; Brian Yoor, EVP, finance & CFO; Roger Bird, SVP, U.S. nutrition; Jaime Contreras, SVP, core laboratory diagnostics, commercial operations; Denis Gestin, SVP, global commercial integration; Elaine Leavenworth, SVP, chief marketing & external affairs officer; Joseph Manning, SVP, international nutrition; Corlis Murray, SVP, quality assurance, regulatory & engineering services; Daniel Salvadori, SVP, established pharmaceuticals, Latin America; Jared Watkin, SVP, diabetes;

100 ABBOTT PARK ROAD
North Chicago, Illinois
60064
USA